The effect of reducing the threshold for carbon monoxide validation of smoking abstinence--evidence from the English Stop Smoking Services.

L. Brose,I. Tombor,L. Shahab,R. West

DOI: https://doi.org/10.1016/j.addbeh.2013.04.006

2013-10-01

Abstract:

What problem does this paper attempt to address?

Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study

A. D. Burden,Y. Okubo,M. Zheng,D. Thaci,P. van de Kerkhof,N. Hu,M. Quaresma,C. Thoma,S. E. Choon

DOI: https://doi.org/10.1111/exd.14824

2023-01-01

Experimental Dermatology

Abstract:Effisayil 1 was a multicentre, randomized, double-blind, placebo-controlled study of the anti-interleukin (IL)-36 receptor monoclonal antibody, spesolimab, in patients presenting with a generalized pustular psoriasis (GPP) flare. Previously published data from this study revealed that within 1 week, rapid pustular and skin clearance were observed in patients receiving spesolimab versus placebo. In this pre-specified subgroup analysis, the efficacy of spesolimab was evaluated according to patient demographic and clinical characteristics at baseline in patients receiving spesolimab (n = 35) or placebo (n = 18) on Day 1. Efficacy was by assessed by achievement of primary endpoint (Generalized Pustular Psoriasis Physician Global Assessment [GPPGA] pustulation subscore of 0 at Week 1) and key secondary endpoint (GPPGA total score of 0 or 1 at Week 1). Safety was assessed at Week 1. Spesolimab was found to be efficacious and had a consistent and favourable safety profile in patients presenting with a GPP flare, regardless of patient demographics and clinical characteristics at baseline.
Efficacy and Safety of Spesolimab in Asian Patients with a Generalized Pustular Psoriasis Flare: Results from the Randomized, Double‐blind, Placebo‐controlled Effisayil™ 1 Study

Akimichi Morita,Tsen-Fang Tsai,Evelyn Yap Wen Yee,Yukari Okubo,Shinichi Imafuku,Min Zheng,Ling Li,Manuel Quaresma,Christian Thoma,Siew Eng Choon

DOI: https://doi.org/10.1111/1346-8138.16609

IF: 3.468

2022-01-01

The Journal of Dermatology

Abstract:Generalized pustular psoriasis is a potentially life-threatening neutrophilic skin disease characterized by recurrent flares of widespread erythema and eruption of sterile pustules. In the Effisayil (TM) 1 study (NCT03782792), 53 patients with a generalized pustular psoriasis flare were treated with placebo or spesolimab, a humanized anti-interleukin-36 receptor monoclonal antibody, the first targeted treatment to be studied in a randomized clinical trial. Spesolimab treatment resulted in rapid pustular and skin clearance, with an acceptable safety profile. Here, we evaluate the efficacy and safety of spesolimab in 29 Asian patients in the Effisayil (TM) 1 study. The primary endpoint, a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of 0 (no visible pustules) at Week 1, was achieved by 10 patients (62.5%) randomized to spesolimab and one patient (7.7%) randomized to placebo (risk difference 54.8, 95% confidence interval [CI] 17.3-79.8). The key secondary endpoint, a GPPGA total score of 0 or 1 (clear or almost clear skin) at Week 1, was achieved by eight (50.0%) and two (15.4%) patients, respectively (risk difference 34.6, 95% CI -3.1-64.7). This was similar to previously published data in the overall population in whom the primary and key secondary endpoints were achieved by 54% versus 6% and 43% versus 11% of patients, respectively. The percentages of Asian patients randomized to spesolimab with a GPPGA pustulation subscore of 0 and GPPGA total score of 0 or 1 were sustained above 60% for up to 12 weeks. In these patients, patient-reported outcomes also improved and markers of systemic inflammation were normalized. Eleven (68.8%) and eight (61.5%) of spesolimab- and placebo-treated patients, respectively, experienced at least one adverse event. In conclusion, spesolimab improved outcomes in Asian patients compared with placebo, supporting its use in the treatment of generalized pustular psoriasis flares.
Spesolimab Treatment for People with Flares of Generalized Pustular Psoriasis: a Plain Language Summary of the Effisayil™ 1 Study

Siew Eng Choon,Slaheddine Marrakchi,A David Burden,Tsen-Fang Tsai,Akimichi Morita,Alexander A Navarini,Min Zheng,Hamida Turki,Milan J Anadkat,Sushmita Rajeswari,Hairui Hua,Sebastian D Vulcu,David Hall,Kay Tetzlaff,Christian Thoma,Mark G Lebwohl

DOI: https://doi.org/10.2217/frd-2022-0002

2022-01-01

Future Rare Diseases

Abstract:What is this study about? Spesolimab is a drug developed to treat worsening disease (known as flares) of generalized pustular psoriasis (shortened to GPP). GPP is a rare disease in which pus-filled blisters or pustules suddenly form all over the body. Before a drug can be approved to treat the symptoms of a disease, clinical studies are performed to test how well it works and whether there are any side effects. This summary reports the results from a clinical study called Effisayil™ 1 that was performed to understand if spesolimab is effective at treating people with GPP flares. What were the results? The study showed that a single dose of spesolimab rapidly cleared pustules and skin lesions (areas of skin affected by redness, pustules, and scaling) within 1 week of treatment, and continued to improve skin lesions for up to 12 weeks. Spesolimab also reduced pain and improved the quality of life of participants over time. Some participants experienced side effects, which were mostly mild or moderate. What do the results of the study mean? The results indicate that spesolimab is an effective treatment for GPP flares. Although spesolimab is not yet available for doctors to prescribe as medication to their patients, the results of this study are currently under review by the official body that approves drugs for use in the USA. Clinical Trial Registration: NCT03782792 ( ClinicalTrials.gov )
33007 Efficacy of spesolimab for the treatment of GPP flares across prespecified patient subgroups in the Effisayil 1 study

A. David Burden,Yukari Okubo,Min Zheng

DOI: https://doi.org/10.1016/j.jaad.2022.06.248

IF: 15.487

2022-01-01

Journal of the American Academy of Dermatology

Abstract:Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening autoinflammatory disease characterized by recurrent flares of sterile pustules that occur with or without systemic inflammation. The 12-week, double-blind, randomized, placebo-controlled Effisayil 1 study (NCT03782792) demonstrated that spesolimab, an anti-interleukin 36 receptor antibody, is associated with rapid pustular and skin clearance in patients with a GPP flare. Here we report the efficacy of spesolimab across prespecified patient subgroups (sex, age, race, body mass index, GPP Physician Global Assessment [GPPGA] pustulation subscore at baseline, GPPGA total score at baseline, Japanese Dermatological Association GPP severity score at baseline, plaque psoriasis at baseline, and IL-36 receptor antagonist gene mutation [IL36RN] status) in Effisayil 1.
Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis

Akimichi Morita,Siew Eng Choon,Hervé Bachelez,Milan J. Anadkat,Slaheddine Marrakchi,Min Zheng,Tsen-Fang Tsai,Hamida Turki,Harry Hua,Sushmita Rajeswari,Christian Thoma,A. David Burden

DOI: https://doi.org/10.1007/s13555-022-00835-6

2022-01-01

Dermatology and Therapy

Abstract:Introduction Generalized pustular psoriasis (GPP) is a rare autoinflammatory skin disease characterized by flares of widespread erythema with sterile pustules, and can be relapsing with recurrent flares, or persistent with intermittent flares. Spesolimab, a humanized anti-interleukin-36 (IL-36) receptor monoclonal antibody, targets the key IL-36 pathogenetic pathway in GPP. A previous study showed that spesolimab treatment led to rapid pustular and skin clearance in patients with GPP flares, which was sustained for up to 12 weeks. This study investigates the long-term effects of spesolimab on GPP flares, for which no specific treatments are currently available. The Effisayil™ 2 study will assess whether maintenance treatment with subcutaneous spesolimab prevents the occurrence of GPP flares and determine the optimal dosing regimen to achieve this aim. Methods Patients will have a documented history of GPP with a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score of 0 or 1 (clear or almost clear) at screening and randomization. Patients will be randomized 1:1:1:1 to three groups receiving a 600-mg subcutaneous loading dose of spesolimab followed by a 300-mg maintenance dose administered every 4 or 12 weeks, or a 300-mg loading dose followed by a 150-mg maintenance dose administered every 12 weeks, and one group receiving placebo, for 48 weeks. The primary endpoint is time to first GPP flare. If a patient experiences a GPP flare during the randomized maintenance treatment period, an open-label intravenous dose of 900-mg spesolimab will be administered, with an option for a second intravenous dose after 1 week. Conclusions Effisayil™ 2 is the first placebo-controlled study in patients with GPP to investigate whether maintenance treatment with spesolimab can prevent flares and provide sustained disease control. This study will provide valuable insights on the long-term management of patients with this potentially life-threatening skin disease. Trial Registration Number NCT04399837.
Effect of Spesolimab on Achieving Sustained Disease Remission in Patients with Generalized Pustular Psoriasis: Results from the Effisayil 2 Study

Kenneth B. Gordon,Curdin Conrad,Mark Lebwohl,Debabrata Bandyopadhyay,Tsen‐Fang Tsai,Joseph F. Merola,Min Zheng,Na Hu,Patrick Hofmann,Christian Thoma,Kilian Eyerich

DOI: https://doi.org/10.25251/skin.7.supp.247

2023-01-01

Abstract:Introduction: Generalized pustular psoriasis (GPP) is a chronic, rare and potentially life-threatening disease characterized by flares of widespread skin pustulation. Sustained skin clearance is a key treatment objective. Intravenous (IV) spesolimab, an anti-interleukin-36 receptor monoclonal antibody, is approved for GPP flare treatment; however, the optimal dosing and long-term efficacy of subcutaneous (SC) spesolimab treatment in patients with GPP has not yet been reported. We report the effect of SC spesolimab on achieving sustained disease remission over 48 weeks in Effisayil 2 (NCT04399837), a trial that evaluated the efficacy and safety of SC spesolimab in preventing GPP flares. Methods: Patients with a history of GPP were randomized (1:1:1:1) to receive placebo (n=31), low- (n=31, 300 mg loading dose [LD]; 150 mg every 12 weeks [q12w]), medium- (n=31, 600 mg LD; 300 mg q12w) or high-dose (n=30, 600 mg LD; 300 mg every 4 weeks [q4w]) SC spesolimab over 48 weeks. Sustained remission was defined as GPP Physician Global Assessment (GPPGA) total score of 0 or 1 at all visits up to Week 48, or GPPGA total score of 0 or 1 and all GPPGA subscores ≤2 at all visits up to Week 48. Sustained pustular clearance was defined as GPPGA pustulation subscore of 0 at all visits from Week 4 to Week 48. Any use of IV spesolimab or another standard of care for GPP worsening was considered a failure of remission. Missing data were imputed by a sequential logistic regression multiple imputation method. Adjusted risk differences (RD) were calculated by the Mantel−Haenszel type-weighted average of differences. Results: 31 patients received placebo, and 30 patients received high-dose spesolimab. Compared to placebo, more patients had sustained remission in the high-dose arm using both GPPGA total score 0 or 1 (63.3% vs 29.0%; RD [95% CI] 0.35 [0.10–0.59]), and GPPGA total score 0 or 1 and all GPPGA subscores ≤2 (60.4% vs 29.0%; RD [95% CI] 0.32 [0.07–0.56]). Compared to placebo, more patients in the high-dose arm had sustained pustular clearance over 48 weeks (63.6% vs 25.8%; RD [95% CI] 0.38 [0.14–0.62]). Conclusion: Overall, high-dose SC spesolimab q4w is effective for the long-term management of GPP skin symptoms.
51856 Spesolimab Rapidly Improves Quality of Life in Patients with Generalized Pustular Psoriasis, As Per Dermatology Life Quality Index Scores: Data from the Effisayil 2 Trial

Alice B. Gottlieb,Bruce Strober,Georgios Kokolakis,Joseph F. Merola,Min Zheng,Richard Langley,Ming Tang,Patrick Hofmann,Christian Thoma,Richard B. Warren

DOI: https://doi.org/10.1016/j.jaad.2024.07.1256

IF: 15.487

2024-01-01

Journal of the American Academy of Dermatology

Abstract:Generalized pustular psoriasis (GPP) is a chronic and potentially life-threatening disease characterized by flares of widespread skin pustulation. In Effisayil 2 (NCT04399837), high-dose spesolimab was superior to placebo in GPP flare prevention and numerically reduced the risk of Dermatology Life Quality Index (DLQI) worsening (≥4-point increase in total score from baseline; secondary endpoint), up to Week 48. Here, we further analyze the effect of high-dose spesolimab versus placebo on DLQI in Effisayil 2. Baseline characteristics were generally similar in the high-dose spesolimab (600 mg loading dose then 300 mg every 4 weeks [N=30]) and placebo groups (N=31) in terms of sex, age, length of disease, and historical flare frequency, although the high-dose spesolimab group had a higher mean±SD DLQI score (11.1±6.9 [missing=1]) versus placebo (7.2±5.6 [missing=0]). At Week 4 in exploratory analysis, more patients in the high-dose spesolimab group (N=29) had no GPP flare and ≥4-point improvement in their DLQI score versus placebo (N=31) (n/N [%]: 10/29 [34.5%] [missing=1] versus 3/31 [9.7%] [missing=0]) at Week 4; this was also seen at Week 48 (11/29 [37.9%] [missing=6] versus 8/31 [25.8%] [missing=0], respectively). Furthermore, a higher proportion of patients treated with spesolimab had no GPP flare and reached a DLQI score of 0 or 1 at all visits up to Week 48 versus placebo (7/29 [24.1%] versus 1/31 [3.2%], respectively). Adding to previous data from Effisayil 2, this analysis demonstrates that patients treated with spesolimab (including high-dose) rapidly gained improvements in DLQI scores versus placebo, which were sustained through to Week 48.
Spesolimab Rapidly Improves Quality of Life in Patients with Generalized Pustular Psoriasis, As Per Dermatology Life Quality Index Scores: Data from the Effisayil 2 Trial

Alice Gottlieb,Bruce Strober,Georgios Kokolakis,Joseph Merola,Min Zheng,Richard Langley,Min Tang,Patrick Hofmann,Christian Thoma,Richard Warren

DOI: https://doi.org/10.25251/skin.8.supp.409

2024-01-01

SKIN The Journal of Cutaneous Medicine

Abstract:Introduction Generalized pustular psoriasis (GPP) is a chronic and potentially life-threatening disease characterized by flares of widespread skin pustulation. In Effisayil 2 (NCT04399837), high‑dose spesolimab was superior to placebo in GPP flare prevention and numerically reduced the risk of Dermatology Life Quality Index (DLQI) worsening (≥4-point increase in total score from baseline; secondary endpoint), up to Week 48. Methods Here, we further analyze the effect of high-dose spesolimab versus placebo on DLQI in Effisayil 2. Results Baseline characteristics were generally similar in the high-dose spesolimab (600 mg loading dose then 300 mg every 4 weeks [N=30]) and placebo groups (N=31) in terms of sex, age, length of disease, and historical flare frequency, although the high‑dose spesolimab group had a higher mean±SD DLQI score (11.1±6.9 [missing=1]) versus placebo (7.2±5.6 [missing=0]). At Week 4 in exploratory analysis, more patients in the high-dose spesolimab group (N=29) had no GPP flare and ≥4-point improvement in their DLQI score versus placebo (N=31) (n/N [%]: 10/29 [34.5%] [missing=1] versus 3/31 [9.7%] [missing=0]) at Week 4; this was also seen at Week 48 (11/29 [37.9%] [missing=6] versus 8/31 [25.8%] [missing=0], respectively). Furthermore, a higher proportion of patients treated with spesolimab had no GPP flare and reached a DLQI score of 0 or 1 at all visits up to Week 48 versus placebo (7/29 [24.1%] versus 1/31 [3.2%], respectively). Conclusion Adding to previous data from Effisayil 2, this analysis demonstrates that patients treated with spesolimab (including high-dose) rapidly gained improvements in DLQI scores versus placebo, which were sustained through to Week 48.
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial

Akimichi Morita,Bruce Strober,A. David Burden,Siew Eng Choon,Milan J. Anadkat,Slaheddine Marrakchi,Tsen-Fang Tsai,Kenneth B. Gordon,Diamant Thaci,Min Zheng,Na Hu,Thomas Haeufel,Christian Thoma,Mark G. Lebwohl

DOI: https://doi.org/10.1016/S0140-6736(23)01378-8

2023-01-01

Abstract:Background Spesolimab is an anti-interleukin-36 receptor monoclonal antibody approved to treat generalised pustular psoriasis (GPP) flares. We aimed to assess the efficacy and safety of spesolimab for GPP flare prevention. Methods This multicentre, randomised, placebo-controlled, phase 2b trial was done at 60 hospitals and clinics in 20 countries. Eligible study participants were aged between 12 and 75 years with a documented history of GPP as per the European Rare and Severe Psoriasis Expert Network criteria, with a history of at least two past GPP flares, and a GPP Physician Global Assessment (GPPGA) score of 0 or 1 at screening and random assignment. Patients were randomly assigned (1:1:1:1) to receive subcutaneous placebo, subcutaneous low-dose spesolimab (300 mg loading dose followed by 150 mg every 12 weeks), subcutaneous medium-dose spesolimab (600 mg loading dose followed by 300 mg every 12 weeks), or subcutaneous high-dose spesolimab (600 mg loading dose followed by 300 mg every 4 weeks) over 48 weeks. The primary objective was to demonstrate a non-flat dose-response curve on the primary endpoint, time to first GPP flare. Findings From June 8, 2020, to Nov 23, 2022, 157 patients were screened, of whom 123 were randomly assigned. 92 were assigned to receive spesolimab (30 high dose, 31 medium dose, and 31 low dose) and 31 to placebo. All patients were either Asian (79 [64%] of 123) or White (44 [36%]). Patient groups were similar in sex distribution (76 [62%] female and 47 [38%] male), age (mean 40 center dot 4 years, SD 15 center dot 8), and GPP Physician Global Assessment score. A non-flat dose-response relationship was established on the primary endpoint. By week 48, 35 patients had GPP flares; seven (23%) of 31 patients in the low-dose spesolimab group, nine (29%) of 31 patients in the medium-dose spesolimab group, three (10%) of 30 patients in the high-dose spesolimab group, and 16 (52%) of 31 patients in the placebo group. High-dose spesolimab was significantly superior versus placebo on the primary outcome of time to GPP flare (hazard ratio [HR]=0 center dot 16, 95% CI 0 center dot 05-0 center dot 54; p=0 center dot 0005) endpoint. HRs were 0 center dot 35 (95% CI 0 center dot 14-0 center dot 86, nominal p=0 center dot 0057) in the low-dose spesolimab group and 0 center dot 47 (0 center dot 21-1 center dot 06, p=0 center dot 027) in the medium-dose spesolimab group. We established a non-flat dose-response relationship for spesolimab compared with placebo, with statistically significant p values for each predefined model (linear p=0 center dot 0022, emax1 p=0 center dot 0024, emax2 p=0 center dot 0023, and exponential p=0 center dot 0034). Infection rates were similar across treatment arms; there were no deaths and no hypersensitivity reactions leading to discontinuation. Interpretation High-dose spesolimab was superior to placebo in GPP flare prevention, significantly reducing the risk of a GPP flare and flare occurrence over 48 weeks. Given the chronic nature of GPP, a treatment for flare prevention is a significant shift in the clinical approach, and could ultimately lead to improvements in patient morbidity and quality of life.Funding Boehringer Ingelheim.Copyright (c) 2023 Elsevier Ltd. All rights reserved.
32924 Sustained Treatment Effect of Spesolimab over 12 Weeks for Generalized Pustular Psoriasis Flares; Results from the Effisayil 1 Study

Boni Elewski,Jonathan Barker,Ulrich Mrowietz,Shinichi Imafuku,Jinhua Xu,Na Hu,Manuel Quaresma,Christian Thoma,Herve Bachelez

DOI: https://doi.org/10.1016/j.jaad.2022.06.858

IF: 15.487

2022-01-01

Journal of the American Academy of Dermatology

Abstract:Generalized pustular psoriasis (GPP) is a rare, life-threatening autoinflammatory disease. In Effisayil 1 (NCT03782792), a double-blind, randomized, placebo-controlled study in patients presenting with a GPP flare, spesolimab, an anti-interleukin 36 receptor antibody, led to rapid clearance (within 1 week) of pustular and skin lesions. Here, we explore the effects of spesolimab over the 12-week study duration, based on observed case analysis. Patients (N = 53) were randomized to receive a single intravenous dose of spesolimab 900 mg (n = 35) or placebo (n = 18) on Day 1.
43008 Effisayil ON, an Open-Label, Long-Term Extension Study of Spesolimab Treatment in Patients with Generalized Pustular Psoriasis: Interim Results for Flare Treatment

Alexander A. Navarini,Herve Bachelez,Siew Eng Choon,Subang Jaya,A. David Burden,Min Zheng,Akimichi Morita,Yuko Tanaka,Binqi Ye,Christian Thoma,Mark G. Lebwohl

DOI: https://doi.org/10.1016/j.jaad.2023.07.178

IF: 15.487

2023-01-01

Journal of the American Academy of Dermatology

Abstract:Generalized pustular psoriasis (GPP) is a rare skin disease, characterized by recurrent flares of extensive, sterile pustular eruption. In patients with a GPP flare in the Effisayil 1 study (NCT03782792), treatment with intravenous spesolimab led to rapid pustular and skin clearance within 1 week. Patients completing Effisayil 1 were offered maintenance treatment with subcutaneous spesolimab (300 mg every 4, 6 or 12 weeks) in the open-label, long-term extension study, Effisayil ON (NCT03886246). We report interim data for patients who received open-label intravenous spesolimab 900 mg treatment for recurrent GPP flares during maintenance treatment in Effisayil ON.
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.

Akimichi Morita,Bruce Strober,A David Burden,Siew Eng Choon,Milan J Anadkat,Slaheddine Marrakchi,Tsen-Fang Tsai,Kenneth B Gordon,Diamant Thaçi,Min Zheng,Na Hu,Thomas Haeufel,Christian Thoma,Mark G Lebwohl

DOI: https://doi.org/10.1016/S0140-6736(23)01378-8

2023-01-01

Abstract:BACKGROUND:Spesolimab is an anti-interleukin-36 receptor monoclonal antibody approved to treat generalised pustular psoriasis (GPP) flares. We aimed to assess the efficacy and safety of spesolimab for GPP flare prevention. METHODS:This multicentre, randomised, placebo-controlled, phase 2b trial was done at 60 hospitals and clinics in 20 countries. Eligible study participants were aged between 12 and 75 years with a documented history of GPP as per the European Rare and Severe Psoriasis Expert Network criteria, with a history of at least two past GPP flares, and a GPP Physician Global Assessment (GPPGA) score of 0 or 1 at screening and random assignment. Patients were randomly assigned (1:1:1:1) to receive subcutaneous placebo, subcutaneous low-dose spesolimab (300 mg loading dose followed by 150 mg every 12 weeks), subcutaneous medium-dose spesolimab (600 mg loading dose followed by 300 mg every 12 weeks), or subcutaneous high-dose spesolimab (600 mg loading dose followed by 300 mg every 4 weeks) over 48 weeks. The primary objective was to demonstrate a non-flat dose-response curve on the primary endpoint, time to first GPP flare. FINDINGS:From June 8, 2020, to Nov 23, 2022, 157 patients were screened, of whom 123 were randomly assigned. 92 were assigned to receive spesolimab (30 high dose, 31 medium dose, and 31 low dose) and 31 to placebo. All patients were either Asian (79 [64%] of 123) or White (44 [36%]). Patient groups were similar in sex distribution (76 [62%] female and 47 [38%] male), age (mean 40·4 years, SD 15·8), and GPP Physician Global Assessment score. A non-flat dose-response relationship was established on the primary endpoint. By week 48, 35 patients had GPP flares; seven (23%) of 31 patients in the low-dose spesolimab group, nine (29%) of 31 patients in the medium-dose spesolimab group, three (10%) of 30 patients in the high-dose spesolimab group, and 16 (52%) of 31 patients in the placebo group. High-dose spesolimab was significantly superior versus placebo on the primary outcome of time to GPP flare (hazard ratio [HR]=0·16, 95% CI 0·05-0·54; p=0·0005) endpoint. HRs were 0·35 (95% CI 0·14-0·86, nominal p=0·0057) in the low-dose spesolimab group and 0·47 (0·21-1·06, p=0·027) in the medium-dose spesolimab group. We established a non-flat dose-response relationship for spesolimab compared with placebo, with statistically significant p values for each predefined model (linear p=0·0022, emax1 p=0·0024, emax2 p=0·0023, and exponential p=0·0034). Infection rates were similar across treatment arms; there were no deaths and no hypersensitivity reactions leading to discontinuation. INTERPRETATION:High-dose spesolimab was superior to placebo in GPP flare prevention, significantly reducing the risk of a GPP flare and flare occurrence over 48 weeks. Given the chronic nature of GPP, a treatment for flare prevention is a significant shift in the clinical approach, and could ultimately lead to improvements in patient morbidity and quality of life. FUNDING:Boehringer Ingelheim.
Design of Effisayil? 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis

Akimichi Morita,Siew Eng Choon,Herve Bachelez,Milan J. Anadkat,Slaheddine Marrakchi,Min Zheng,Tsen-Fang Tsai,Hamida Turki,Harry Hua,Sushmita Rajeswari,Christian Thoma,A. David Burden

DOI: https://doi.org/10.1007/s13555-022-00835-6

2023-01-01

Dermatology and Therapy

Abstract:Introduction Generalized pustular psoriasis (GPP) is a rare autoinflammatory skin disease characterized by flares of widespread erythema with sterile pustules, and can be relapsing with recurrent flares, or persistent with intermittent flares. Spesolimab, a humanized anti-interleukin-36 (IL-36) receptor monoclonal antibody, targets the key IL-36 pathogenetic pathway in GPP. A previous study showed that spesolimab treatment led to rapid pustular and skin clearance in patients with GPP flares, which was sustained for up to 12 weeks. This study investigates the long-term effects of spesolimab on GPP flares, for which no specific treatments are currently available. The Effisayil (TM) 2 study will assess whether maintenance treatment with subcutaneous spesolimab prevents the occurrence of GPP flares and determine the optimal dosing regimen to achieve this aim. Methods Patients will have a documented history of GPP with a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score of 0 or 1 (clear or almost clear) at screening and randomization. Patients will be randomized 1:1:1:1 to three groups receiving a 600-mg subcutaneous loading dose of spesolimab followed by a 300-mg maintenance dose administered every 4 or 12 weeks, or a 300-mg loading dose followed by a 150-mg maintenance dose administered every 12 weeks, and one group receiving placebo, for 48 weeks. The primary endpoint is time to first GPP flare. If a patient experiences a GPP flare during the randomized maintenance treatment period, an open-label intravenous dose of 900-mg spesolimab will be administered, with an option for a second intravenous dose after 1 week. Conclusions Effisayil (TM) 2 is the first placebo-controlled study in patients with GPP to investigate whether maintenance treatment with spesolimab can prevent flares and provide sustained disease control. This study will provide valuable insights on the long-term management of patients with this potentially life-threatening skin disease. Plain Language Summary The aim of the Effisayil (TM) 2 study is to see whether long-term treatment with the antibody spesolimab helps prevent skin flares in people with generalized pustular psoriasis (GPP). Patients can take part in the Effisayil (TM) 2 study if they have well-controlled GPP before they begin treatment in the study; that is, they will have skin that is clear or almost clear. Patients will be randomly divided into four groups, with similar numbers of patients in each group. In three of the four groups, patients will be given different doses of spesolimab for 48 weeks. In the fourth group, patients will be given a placebo for 48 weeks. The main goal of the study is to see how long it takes patients to have a GPP flare, while they are being given spesolimab or placebo. If any patient has a GPP flare during the study, they can be treated with another dose of spesolimab (and possibly a second dose 1 week later if needed), to help control the GPP flare. In this way, the Effisayil (TM) 2 study will help doctors and patients to learn how to manage GPP over time, so that GPP flares can be avoided.
43754 Efficacy and Safety of Spesolimab for the Treatment of Generalized Pustular Psoriasis Flares in Hospitalized Versus Non-Hospitalized Patients

Yukari Okubo

DOI: https://doi.org/10.1016/j.jaad.2023.07.171

IF: 15.487

2023-01-01

Journal of the American Academy of Dermatology

Abstract:Generalized pustular psoriasis (GPP) is a rare skin disease associated with excess hospital admissions. In Effisayil 1 (NCT03782792), spesolimab treatment led to rapid pustular and skin clearance, with a favorable safety profile, in patients with GPP flares. We report the eﬃcacy and safety of spesolimab in hospitalized and non-hospitalized patients. Overall, 51/53 patients in Effisayil 1 had hospitalization data: 25 (spesolimab, 17; placebo, 8) were hospitalized due to a GPP flare at randomization (median length of stay, 8.0 days); 26 were not hospitalized (spesolimab, 16; placebo, 10). Baseline demographics were similar between spesolimab and placebo treatment groups independent of hospitalization status.
Spesolimab Treatment for the Prevention of Flares in People with Generalized Pustular Psoriasis (GPP): a Plain Language Summary of the Effisayil™ 2 Study

Akimichi Morita,Bruce Strober,A David Burden,Siew Eng Choon,Milan J Anadkat,Slaheddine Marrakchi,Tsen-Fang Tsai,Kenneth B Gordon,Diamant Thaçi,Min Zheng,Na Hu,Thomas Haeufel,Christian Thoma,Mark G Lebwohl

DOI: https://doi.org/10.2217/frd-2023-0023

2024-01-01

Future Rare Diseases

Abstract:What is this study about? Generalized pustular psoriasis (shortened to GPP) is a rare, potentially life-threatening disease in which pus-filled blisters or pustules may suddenly form all over the body. The drug spesolimab has been approved to treat worsening GPP (known as flares) in many countries. However, it was not known if spesolimab could prevent the symptoms of GPP. This summary reports the results from a clinical study called Effisayil™ 2, that was done to understand if spesolimab was a safe and effective way to prevent flares in people with GPP. In the study, 123 participants, recruited in 20 different countries, were given one of three different doses of spesolimab (low, medium, or high) or a non-active medicine (placebo) over 48 weeks. What were the results? Participants who received spesolimab had fewer GPP flares over the course of the 48-week study. Different doses of the drug were tested and compared to placebo, and a high dose of spesolimab worked better than low and medium doses. Using spesolimab also reduced the chance of developing skin symptoms, such as redness or pustules, and prevented quality of life getting worse over 48 weeks. While some participants experienced unwanted effects, they were mostly mild or moderate and most did not appear to be caused by spesolimab, or the dose at which it was given. What do the results of the study mean? The results indicate that a high dose of spesolimab works well to prevent GPP flares and stop the disease getting worse. Health authorities are looking at the results of this study to decide if spesolimab can also be prescribed for the prevention of GPP flares.
Study Protocol of the Global Effisayil 1 Phase II, Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial of Spesolimab in Patients with Generalized Pustular Psoriasis Presenting with an Acute Flare

Siew Eng Choon,Mark G. Lebwohl,Slaheddine Marrakchi,A. David Burden,Tsen-Fang Tsai,Akimichi Morita,Alexander A. Navarini,Min Zheng,Jinhua Xu,Hamida Turki,Sushmita Rajeswari,Hongjie Deng,Kay Tetzlaff,Christian Thoma,Herve Bachelez

DOI: https://doi.org/10.1136/bmjopen-2020-043666

IF: 3.006

2021-01-01

BMJ Open

Abstract:Introduction Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening disease characterised by recurrent flares of widespread neutrophilic aseptic skin pustular eruption. Despite the availability of approved biologics for GPP in Japan, Taiwan and Thailand, associated evidence is largely based on uncontrolled studies in which acute flares were not directly assessed. Therefore, there is a high unmet need to investigate new rapid-acting effective treatments that resolve symptoms associated with acute GPP flares. A prior Phase I proof-of-concept study showed rapid improvements in skin and pustule clearance with a single intravenous dose of spesolimab, a novel anti-interleukin-36 receptor antibody, in patients presenting with an acute GPP flare. Here, we present the design and rationale of Effisayil 1, a global, Phase II, placebo-controlled study to evaluate the efficacy, safety and tolerability of spesolimab in patients presenting with an acute GPP flare.Methods and analysis At least 51 patients with an acute GPP flare will be randomised 2:1 to receive a single 900 mg intravenous dose of spesolimab or placebo and followed for up to 28 weeks. The primary endpoint is a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of 0 (pustule clearance) at Week 1. The key secondary endpoint is a GPPGA score of 0 or 1 (clear or almost clear) at Week 1. Safety will be assessed over the study duration by the occurrence of treatment-emergent adverse events. Blood and skin biopsies will be collected to assess biomarkers. Superiority of spesolimab over placebo in the proportion of patients achieving the primary and key secondary endpoints will be evaluated.Ethics and dissemination The study complies with the ethical principles of the Declaration of Helsinki, the International Council for Harmonisation’s Good Clinical Practice and local regulations. Ethics committee approvals have been obtained for each centre from all participating countries and are listed in online supplementary file 1. Primary results will be published in a peer-reviewed journal.Trial registration details ClinicalTrials.gov identifier: NCT03782792; Pre-results.
Extravascular contribution of blood oxygenation level‐dependent signal changes: A numerical analysis based on a vascular network model

N. Fujita

DOI: https://doi.org/10.1002/mrm.1251

2001-10-01

Magnetic Resonance in Medicine

Abstract:In this study, the extravascular (EV) contribution to blood oxygenation level‐dependent (BOLD) signal changes was evaluated, based on a numerical analysis of the nondimensional Bloch‐Torrey equation for a vascular network model of randomly oriented paramagnetic vessels. From a statistical point of view, the susceptibility‐induced EV BOLD signal changes for both gradient‐ and spin‐echoes are shown to be proportional to cerebral blood volume (CBV). These changes can be expressed by a function of two nondimensional parameters: one represents the characteristic phase change of the signal induced by the deoxyhemoglobin‐containing vessels, and the other represents a diffusion effect relative to the vessel radius. The numerical results showed excellent agreement with the analytical solutions obtained previously for the regimes of small and large diffusion effects. Based on the numerical results for gradient‐ and spin‐echoes, it is possible to show the dependence of the EV BOLD contribution on the echo time, the static magnetic field strength, and the stimulation‐induced CBV change. This dependence can be demonstrated for vessels of small, intermediate, and large radii, which correspond respectively to the slow, intermediate, and fast diffusion regimes. A more realistic functional MRI (fMRI) simulation which includes an intravascular (IV) contribution is presented, with emphasis on the field strength dependence of the BOLD signal changes. Magn Reson Med 46:723–734, 2001. © 2001 Wiley‐Liss, Inc.
Real-World Efficacy of Spesolimab: Reports from Four Patients with Generalized Pustular Psoriasis

Joe Tung,Jacquelyn Dorsal,Laura Rezac,Thomas Selby

DOI: https://doi.org/10.25251/skin.8.supp.370

2024-03-18

SKIN The Journal of Cutaneous Medicine

Abstract:Introduction: Generalized pustular psoriasis (GPP) is a rare, chronic, autoinflammatory skin disease characterized by widespread pustular eruptions that may be accompanied by systemic symptoms. GPP is painful, distressing, and adversely affects patient quality of life (QoL). Spesolimab is a first-in-class anti-IL-36 receptor monoclonal antibody approved for the treatment of GPP flares. Methods: We describe 4 cases from our respective clinical practices, where individuals with GPP were treated successfully with spesolimab. Results: Four patient cases of GPP were included; an 18-year-old male, a 58-year-old female; a 36-year-old male, and a 40-year-old female. One patient had a history of GPP, and had experienced 3 prior flares in the preceding year. Two patients had a history of plaque psoriasis. Events preceding the current GPP flare included hydroxychloroquine treatment (n=2), and corticosteroid treatment (n=3). All patients presented with sudden onset of worsening pustular rash (affecting lower extremities [n=1]; extremities and trunk [n=1]; whole body [n=2]). Two patients had systemic symptoms at presentation (1 case: fever, chills, malaise, fatigue; 1 case: severe weakness), and required hospitalization. Two patients received an initial mis-diagnosis of acute generalized exanthematous pustulosis (AGEP). Significant impacts on QoL were reported; all 4 patients were unable to perform normal daily activities; the 18-year-old patient was targeted at school because the skin lesions were perceived to be contagious. The 4 patients received multiple therapies prior to, and concomitantly with, spesolimab treatment, including topical agents, antibiotics, corticosteroids, retinoids, immunosuppressants, and biologics. All 4 patients received two 900 mg intravenous infusions of spesolimab with treatment intervals between 7 and 20 days. Treatment was given at an outpatient infusion center (n=3*), or using a home infusion service (n=1); *1 patient received their first infusion as an inpatient. Significant clinician-assessed improvement in pustules occurred within 1 week of the first spesolimab infusion in 3 patients; the remaining patient reported improvement 1-2 weeks after the second infusion. One of the hospitalized patients experienced 75% improvement in itching, pain, and pustules within 24 hours of the first spesolimab infusion, and was discharged the next day. Spesolimab treatment also improved QoL, with patients experiencing rapid improvements in pain, and their ability to resume their normal daily activities. Conclusions: These cases demonstrate the efficacy of spesolimab in the real-world, highlighting the ability of spesolimab treatment to rapidly improve GPP symptoms and patient QoL. Administration of spesolimab in an inpatient setting allowed for rapid patient improvement and discharge the next day. These cases also highlight the association of certain drugs as triggers for GPP flares, as well as the importance of AGEP in the differential diagnosis of GPP
Spesolimab for generalized pustular psoriasis: a review of two key clinical trials supporting initial US regulatory approval

Eran C Gwillim,Anna J Nichols

DOI: https://doi.org/10.3389/fimmu.2024.1359481

2024-07-22

Abstract:Generalized pustular psoriasis (GPP) is a chronic, rare, and potentially life-threatening inflammatory disease, characterized by the rapid and widespread eruption of small, sterile pustules with surrounding skin erythema. Abnormal signaling of the interleukin-36 (IL-36) pathway appears to have a central role in GPP immunopathology, and provides a rational therapeutic target. Spesolimab is a first-in-class humanized monoclonal antibody that binds specifically to the IL-36 receptor, and antagonizes IL-36 signaling. Spesolimab obtained regulatory approval in the United States (US) in September 2022 for use in the treatment of GPP flares in adults, and was subsequently approved for GPP flare treatment in many other countries across the world. Recently, regulatory approval was granted for subcutaneous dosing of spesolimab for treatment of GPP when not experiencing a flare. Here, we review data from two key clinical trials that supported the initial US regulatory approval; namely, the phase 1 proof-of-concept trial (ClinicalTrials.gov ID, NCT02978690), and Effisayil™ 1 (NCT03782792), which remains the largest and only randomized clinical trial in patients experiencing GPP flares published to date. In the phase 1 proof-of-concept trial, a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score of 0 or 1 (clear or almost clear skin) was attained in 5/7 (71%) patients by week 1 and in all 7 patients by week 4; and the mean percent improvement in the Generalized Pustular Psoriasis Area and Severity Index (GPPASI) score from baseline was 59.0% at week 1, 73.2% at week 2, and 79.8% at week 4. In Effisayil™ 1, a GPPGA pustulation subscore of 0 (no visible pustules) was achieved in 19/35 (54%) patients receiving spesolimab at the end of week 1, versus 1/18 (6%) receiving placebo (difference, 49 percentage points; 95% confidence interval [CI], 21 to 67; P<0.001); and a GPPGA total score of 0 or 1 was achieved by 15/35 (43%) patients in the spesolimab group, versus 2/18 (11%) patients in the placebo group (difference, 32 percentage points; 95% CI, 2 to 53; P = 0.02). Infections at week 1 were reported in 6/35 (17%) patients receiving spesolimab and in 1/18 (6%) patients receiving placebo. These data demonstrate the efficacy and safety of spesolimab in providing rapid and sustained clinical improvement for patients with GPP flares, which translates into improved quality of life, by offering a targeted therapy for GPP.
Spesolimab, the first‐in‐class anti‐IL‐36R antibody: From bench to clinic

Akimichi Morita,Yukari Okubo,Shinichi Imafuku,Tadashi Terui

DOI: https://doi.org/10.1111/1346-8138.17449

IF: 3.468

2024-10-09

The Journal of Dermatology

Abstract:Inflammatory diseases that are driven by several pro‐inflammatory cytokines has resulted in in the development of targeted therapies across different disease settings. Interleukin (IL)‐36 cytokines have been implicated in several inflammatory diseases. In this review we describe the scientific evidence surrounding the use of the IL‐36 receptor (IL‐36R)‐targeting antibody, spesolimab, in IL‐36‐mediated skin diseases: generalized pustular psoriasis (GPP), palmoplantar pustulosis (PPP), hidradenitis suppurativa, and Netherton syndrome (NS). Spesolimab, a high affinity, specific, humanized, antagonistic immunoglobulin G1 antibody, targets the IL‐36R at a binding site distinct from its agonists, IL‐36α/β/γ, and at least one endogenous antagonist, IL‐36R antagonist. In vitro and in vivo data for spesolimab show effective inhibition of IL‐36R‐mediated signaling pathways, and six Phase I studies in healthy volunteers presented a favorable safety and pharmacokinetic (PK) profile, leading to the development of a clinical trial program to evaluate spesolimab in the treatment of IL‐36R‐mediated diseases. Six studies (including an expanded access program) have evaluated the efficacy, safety, PKs, and pharmacogenomics of spesolimab in patients with GPP flares. Spesolimab treatment of GPP flares resulted in rapid and sustained improvements in pustular and skin clearance, and clinically significant improvements in patient‐reported symptoms and quality of life. Spesolimab also significantly reduces the risk of GPP flares and flare occurrence, preventing disease worsening and has a favorable safety profile. There have been three trials of spesolimab in PPP; further evaluation is needed to better define those patients who might benefit from the treatment. A trial of spesolimab in NS is ongoing, while other spesolimab trials suggest that IL‐36 may only play a secondary role in the pathogenesis of atopic dermatitis. In conclusion, research into spesolimab has provided much needed insight into the role of IL‐36 in the human immune system and the mechanism behind IL‐36‐mediated inflammatory diseases. Spesolimab provides an efficacious targeted treatment for GPP, a disease with a high unmet medical need.

dermatology

The effect of reducing the threshold for carbon monoxide validation of smoking abstinence--evidence from the English Stop Smoking Services.

Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study

Efficacy and Safety of Spesolimab in Asian Patients with a Generalized Pustular Psoriasis Flare: Results from the Randomized, Double‐blind, Placebo‐controlled Effisayil™ 1 Study

Spesolimab Treatment for People with Flares of Generalized Pustular Psoriasis: a Plain Language Summary of the Effisayil™ 1 Study

33007 Efficacy of spesolimab for the treatment of GPP flares across prespecified patient subgroups in the Effisayil 1 study

Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis

Effect of Spesolimab on Achieving Sustained Disease Remission in Patients with Generalized Pustular Psoriasis: Results from the Effisayil 2 Study

51856 Spesolimab Rapidly Improves Quality of Life in Patients with Generalized Pustular Psoriasis, As Per Dermatology Life Quality Index Scores: Data from the Effisayil 2 Trial

Spesolimab Rapidly Improves Quality of Life in Patients with Generalized Pustular Psoriasis, As Per Dermatology Life Quality Index Scores: Data from the Effisayil 2 Trial

Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial

32924 Sustained Treatment Effect of Spesolimab over 12 Weeks for Generalized Pustular Psoriasis Flares; Results from the Effisayil 1 Study

43008 Effisayil ON, an Open-Label, Long-Term Extension Study of Spesolimab Treatment in Patients with Generalized Pustular Psoriasis: Interim Results for Flare Treatment

Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.

Design of Effisayil? 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis

43754 Efficacy and Safety of Spesolimab for the Treatment of Generalized Pustular Psoriasis Flares in Hospitalized Versus Non-Hospitalized Patients

Spesolimab Treatment for the Prevention of Flares in People with Generalized Pustular Psoriasis (GPP): a Plain Language Summary of the Effisayil™ 2 Study

Study Protocol of the Global Effisayil 1 Phase II, Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial of Spesolimab in Patients with Generalized Pustular Psoriasis Presenting with an Acute Flare

Extravascular contribution of blood oxygenation level‐dependent signal changes: A numerical analysis based on a vascular network model

Real-World Efficacy of Spesolimab: Reports from Four Patients with Generalized Pustular Psoriasis

Spesolimab for generalized pustular psoriasis: a review of two key clinical trials supporting initial US regulatory approval

Spesolimab, the first‐in‐class anti‐IL‐36R antibody: From bench to clinic